The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Johnson & Johnson begins U.S. push into soft-tissue robotic surgery after FDA De Novo nod for OTTAVA
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 10, 8:54 AM EDT

Johnson & Johnson begins U.S. push into soft-tissue robotic surgery after FDA De Novo nod for OTTAVA

FDA De Novo authorization gives Johnson & Johnson’s robotic surgical system a clearer path to adoption in the U.S., intensifying competition with Intuitive Surgical, the dominant player in surgical robotics.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Johnson & Johnson has formally moved into the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA robotic surgical system, according to a market report published Tuesday.

De Novo is a specific FDA pathway used when a device has no legally marketed equivalent, allowing the agency to grant authorization based on safety and effectiveness for that new category of technology. In this case, the approval positions OTTAVA to compete in a market that has been largely shaped by Intuitive Surgical’s da Vinci platform and related offerings.

The market report frames the new authorization as a direct competitive challenge to Intuitive Surgical, which is represented by the ticker ISRG. Intuitive Surgical has long been the main U.S. supplier for robotic-assisted procedures, and its installed base has helped drive recurring demand through system placements, procedure volumes, and service and instrument revenue streams.

Johnson & Johnson’s entry through OTTAVA is noteworthy not only for who it challenges, but also because it indicates that a major diversified healthcare company is still willing to spend and seek regulatory clearance in a surgical technology category that requires substantial clinical evidence, surgeon training, and long-term support.

For investors and customers, the practical question will be how quickly OTTAVA can translate FDA authorization into real-world use. While De Novo approval indicates FDA clearance for the intended device category, widespread adoption typically depends on hospital evaluations, credentialing and training for surgeons and staff, and the availability and pricing of the system’s consumables and service coverage.

Still, the report does not provide additional operational detail, such as which specific soft-tissue indications OTTAVA is cleared to address, how the company expects to deploy the system commercially, or what timeline it is using for broader rollout. Without those specifics, it is unclear how fast Johnson & Johnson can convert the regulatory milestone into meaningful procedure volumes or revenue.

In the meantime, the timing matters for the competitive landscape. Intuitive Surgical’s business model is closely tied to the growth of robotic procedures, particularly as health systems weigh the clinical workflow and economics of robotic-assisted surgery against conventional approaches.

What to watch next is whether Johnson & Johnson follows the FDA authorization with clearer commercial disclosures, such as deployment plans, payer and hospital adoption indicates, and any updates on how the OTTAVA system will be supported post-sale. The next milestones will likely be incremental: additional regulatory data, early site announcements, and evidence of growing procedure activity.

Why It Matters

  • Intuitive Surgical’s leadership in surgical robotics could face increased competition as a major incumbent seeks U.S. adoption for OTTAVA.
  • Regulatory authorization is only the first step in a market where hospitals evaluate clinical workflow and total cost of ownership over time.
  • If OTTAVA scales, competitive pressure could show up in system placement dynamics, service offerings, and instrument demand across health systems.
  • The lack of disclosed rollout specifics means investors and providers will be watching for additional indicates on adoption pace and target procedure categories.

Sources

Key Facts

  • Johnson & Johnson received FDA De Novo authorization for its OTTAVA robotic surgical system.
  • The authorization is described as an entry into the U.S. soft-tissue robotic surgery market.
  • The De Novo pathway is used by the FDA for novel devices without a legally marketed equivalent.
  • The market report casts the OTTAVA authorization as a competitive challenge to Intuitive Surgical (ISRG).
  • The report does not provide further commercial rollout details such as indications, timeline, or revenue expectations.

Healthcare Related

Johnson & Johnson begins U.S. push into soft-tissue robotic surgery after FDA De Novo nod for OTTAVA | The Apex Times